Hepatitis Test Solution Diagnosis Market Share

Quest Diagnostics, Inc. is a diagnostic testing organization as of July 2023. Recently, DGX revised their documentation regarding Alzheimer's disease and Hepatitis C tests. The organization published a report authored by CDC experts and utilizing data from the Quest Diagnostics Health Trends research program in order to bolster public health policy concerning HIV, hepatitis, COVID-19, and various other diseases. With the most recent introduction, Quest Diagnostics will enhance the Diagnostic Solutions division by expanding its range of testing services. DGX is dedicated to the advancement of state-of-the-art laboratory assays that assist in the evaluation of patients' susceptibility to dementia and other degenerative disorders. It is for the first time offering patients and clinicians across the nation access to cutting-edge laboratory technology for Alzheimer's disease via its AD-Detect collection of blood tests. 

The Elecsys HCV Duo, which permits simultaneous and independent determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample, is the first entirely automated immunoassay commercially available in India as of July 2023. This suggests that the test has the potential to identify infection even during its nascent phases, while the patient is recovering from the virus, or even in the presence of chronic illness. Viral hepatitis is progressively gaining recognition as a significant public health concern in India. 

The number of HCV carriers is estimated to be between 12 and 13 million, and predictive models suggest that the disease burden will experience a substantial increase in the near future. Paradoxically, a mere 30% of individuals diagnosed with chronic HCV infection initiate therapy, while a mere 19% are cognizant of their diagnosis. Individuals who are in the early stages of the illness are unaware of their medical condition. Consequently, a substantial disparity exists between the time of diagnosis and the initiation of treatment.

Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.

However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.

Hepatitis Diagnostic Test Solution Market Segment Insights

Hepatitis Diagnostic Test Solution Type Insights

Hepatitis Diagnostic Test Solution Technology Insights

Based on the type of technology, the Hepatitis Diagnostic Test Solution industry at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.

Hepatitis Diagnostic Test Solution End User Insights

Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others

Hepatitis Diagnostic Test Solution Regional Insights

The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Hepatitis Diagnostic Test Solution market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Hepatitis Diagnostic Test Solution market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Hepatitis Diagnostic Test Solution market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Hepatitis Diagnostic Test Solution market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the Hepatitis Diagnostic Test Solution industry, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.

Europe is expected to be the second-largest region in the Hepatitis Diagnostic Test Solution industry, owing to the growing detection of hepatitis virus cases in the region.

The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body’s response to the hepatitis virus.

Thus, the Hepatitis Diagnostic Test Solution market in APAC is expected to hold the third-largest share during the forecast period.

The Middle East & Africa is expected to hold the least share of the Hepatitis Diagnostic Test Solution market during the forecast due to the slow economic development, especially in Africa.

Some of the Key Players operating in the Hepatitis Diagnostic Test Solution Market are: 

• Abbott


• Biomérieux Sa


• Bio-Rad Laboratories, Inc.


• Danaher


• DiaSorin S.p.A.


• Miraca Holdings Inc. (Fujirebio, Inc.)


• Grifols


• Onsite Lab Holding AG (MedMira, Inc.)


• Qiagen


• Roche Holding AG (Roche Diagnostics)


• Siemens (Siemens Healthineers)


• Sandoz International GmbH

Hepatitis Diagnostic Test Solution Market Segmentation

Hepatitis Diagnostic Test Solution Disease Type Outlook

• Hepatitis A


• Hepatitis B


• Hepatitis C


• Others

Hepatitis Diagnostic Test Solution Type of Technology Outlook

• Nucleic Acid Testing (NAT)


• Enzyme-Linked Immunosorbent Assay (ELISA)


• Rapid Diagnostic Tests (RDT)


• Chemiluminescence Immunoassay (CLIA)


• Genotyping


• Others

Hepatitis Diagnostic Test Solution End User Outlook

• Hospitals


• Diagnostic Laboratories


• Blood Banks


• Research institutes


• Others

Intended Audience

• Pharmaceutical companies


• Government and private laboratories


• Research and development (R&D) companies


• Research laboratories


• Market research and consulting service providers